IS2208B - Quinoline afleiður - Google Patents
Quinoline afleiðurInfo
- Publication number
- IS2208B IS2208B IS5775A IS5775A IS2208B IS 2208 B IS2208 B IS 2208B IS 5775 A IS5775 A IS 5775A IS 5775 A IS5775 A IS 5775A IS 2208 B IS2208 B IS 2208B
- Authority
- IS
- Iceland
- Prior art keywords
- quinoline derivatives
- quinoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
PCT/SE1999/001270 WO2000003991A1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
IS5775A IS5775A (is) | 2000-12-18 |
IS2208B true IS2208B (is) | 2007-02-15 |
Family
ID=20412093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS5775A IS2208B (is) | 1998-07-15 | 2000-12-18 | Quinoline afleiður |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1095021B1 (is) |
JP (1) | JP4045070B2 (is) |
KR (1) | KR100516382B1 (is) |
CN (1) | CN1157378C (is) |
AP (1) | AP1366A (is) |
AT (1) | ATE250036T1 (is) |
AU (1) | AU751103B2 (is) |
BR (1) | BR9912109B1 (is) |
CA (1) | CA2336968C (is) |
CZ (1) | CZ300229B6 (is) |
DE (1) | DE69911415T2 (is) |
DK (1) | DK1095021T3 (is) |
EE (1) | EE04673B1 (is) |
ES (1) | ES2205854T3 (is) |
HK (1) | HK1035715A1 (is) |
HR (1) | HRP20010039B1 (is) |
HU (1) | HU229427B1 (is) |
ID (1) | ID27423A (is) |
IL (2) | IL140346A0 (is) |
IS (1) | IS2208B (is) |
ME (1) | ME00374B (is) |
NO (1) | NO317601B1 (is) |
NZ (1) | NZ508923A (is) |
OA (1) | OA11906A (is) |
PL (1) | PL199783B1 (is) |
PT (1) | PT1095021E (is) |
RS (1) | RS50128B (is) |
RU (1) | RU2213733C2 (is) |
SE (1) | SE9802549D0 (is) |
TR (1) | TR200100087T2 (is) |
UA (1) | UA64791C2 (is) |
WO (1) | WO2000003991A1 (is) |
ZA (1) | ZA200007593B (is) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395750B1 (en) * | 1999-10-25 | 2002-05-28 | Active Biotech Ab | Drugs for the treatment of malignant tumors |
SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
AU2003242127A1 (en) * | 2002-06-05 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
AU2003242124A1 (en) * | 2002-06-11 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Medicament for treatment of neurodegenerative diseases |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
NZ592897A (en) | 2005-10-19 | 2012-12-21 | Teva Pharma | Crystals of laquinimod sodium, and process for the manufacture thereof |
EP2035001B1 (en) | 2006-06-12 | 2011-11-09 | Teva Pharmaceutical Industries Limited | Stable laquinimod preparations |
WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
SI2234485T1 (sl) | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stabilni lakvinimodni pripravki |
NZ591315A (en) | 2008-09-03 | 2012-08-31 | Teva Pharma | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
CN102480960A (zh) | 2009-07-30 | 2012-05-30 | 泰华制药工业有限公司 | 利用拉喹莫德治疗克隆氏病 |
AU2010282948C1 (en) | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
BR112012021905A2 (pt) | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
EP2542079B1 (en) | 2010-03-03 | 2014-05-21 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
AR082150A1 (es) | 2010-07-09 | 2012-11-14 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio |
RS54002B1 (en) * | 2010-08-27 | 2015-10-30 | Grünenthal GmbH | SUBSTITUTED 2-OXO AND 2-THIOXO-DIHYDROCHINOLINE-3-CARBOXAMIDES AS KCNQ2 / 3 MODULATORS |
KR20130065728A (ko) * | 2010-10-14 | 2013-06-19 | 임뮤나르 에이비 | Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드 |
EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
CN103974704A (zh) | 2011-10-12 | 2014-08-06 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
KR20140138725A (ko) | 2012-02-16 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도 |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
CA2890194A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
JP5868839B2 (ja) | 2012-12-27 | 2016-02-24 | 三菱重工業株式会社 | チャー払出管 |
WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
SG11201608674UA (en) | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
CN108358842A (zh) * | 2014-08-28 | 2018-08-03 | 杭州普晒医药科技有限公司 | 他喹莫德的晶型及其制备方法、其药物组合物和用途 |
US9956212B2 (en) | 2014-09-23 | 2018-05-01 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
CN107072989B (zh) | 2014-11-19 | 2020-07-03 | 活跃生物技术有限公司 | 用于治疗白血病的喹啉甲酰胺 |
EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
WO2018105943A1 (ko) * | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
EP4114368A1 (en) | 2020-03-03 | 2023-01-11 | Active Biotech AB | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
EP4185292A1 (en) | 2020-07-23 | 2023-05-31 | Erasmus University Rotterdam Medical Center | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
WO2022152902A1 (en) | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
BR112023023715A2 (pt) | 2021-05-25 | 2024-02-20 | Active Biotech Ab | Pluralidade de partículas compreendendo tasquinimod, composição farmacêutica, unidade de dosagem farmacêutica, uso da pluralidade de partículas ou da composição farmacêutica, e, método para o tratamento do câncer |
CA3221689A1 (en) | 2021-07-02 | 2023-01-05 | Hans Wannman | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE469368B (sv) * | 1991-10-09 | 1993-06-28 | Kabi Pharmacia Ab | Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms) |
SE9201076L (sv) * | 1992-04-06 | 1993-10-07 | Shimon Slavin | Användningen av gamla läkemedel för behandling av diabetes |
JPH07224040A (ja) * | 1994-02-07 | 1995-08-22 | Fujisawa Pharmaceut Co Ltd | キノリン誘導体 |
GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
SE9400810D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of Quinoline-3-carboxamide compounds |
GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-07-15 SE SE9802549A patent/SE9802549D0/xx unknown
-
1999
- 1999-07-14 OA OA00100011A patent/OA11906A/en unknown
- 1999-07-14 NZ NZ508923A patent/NZ508923A/xx not_active IP Right Cessation
- 1999-07-14 JP JP2000560098A patent/JP4045070B2/ja not_active Expired - Fee Related
- 1999-07-14 CZ CZ20010094A patent/CZ300229B6/cs not_active IP Right Cessation
- 1999-07-14 RU RU2001104342/04A patent/RU2213733C2/ru not_active IP Right Cessation
- 1999-07-14 HU HU0103224A patent/HU229427B1/hu not_active IP Right Cessation
- 1999-07-14 PT PT99933452T patent/PT1095021E/pt unknown
- 1999-07-14 EP EP99933452A patent/EP1095021B1/en not_active Expired - Lifetime
- 1999-07-14 IL IL14034699A patent/IL140346A0/xx active IP Right Grant
- 1999-07-14 DE DE69911415T patent/DE69911415T2/de not_active Expired - Lifetime
- 1999-07-14 KR KR10-2000-7014618A patent/KR100516382B1/ko not_active IP Right Cessation
- 1999-07-14 ME MEP-2008-574A patent/ME00374B/me unknown
- 1999-07-14 ES ES99933452T patent/ES2205854T3/es not_active Expired - Lifetime
- 1999-07-14 CA CA002336968A patent/CA2336968C/en not_active Expired - Fee Related
- 1999-07-14 EE EEP200100010A patent/EE04673B1/xx unknown
- 1999-07-14 PL PL345388A patent/PL199783B1/pl unknown
- 1999-07-14 AU AU49504/99A patent/AU751103B2/en not_active Ceased
- 1999-07-14 BR BRPI9912109-3A patent/BR9912109B1/pt not_active IP Right Cessation
- 1999-07-14 WO PCT/SE1999/001270 patent/WO2000003991A1/en not_active Application Discontinuation
- 1999-07-14 UA UA2000127299A patent/UA64791C2/uk unknown
- 1999-07-14 RS YUP-15/01A patent/RS50128B/sr unknown
- 1999-07-14 CN CNB998085987A patent/CN1157378C/zh not_active Expired - Fee Related
- 1999-07-14 TR TR2001/00087T patent/TR200100087T2/xx unknown
- 1999-07-14 DK DK99933452T patent/DK1095021T3/da active
- 1999-07-14 AP APAP/P/2001/002041A patent/AP1366A/en active
- 1999-07-14 ID IDW20010331A patent/ID27423A/id unknown
- 1999-07-14 AT AT99933452T patent/ATE250036T1/de active
-
2000
- 2000-12-14 IL IL140346A patent/IL140346A/en not_active IP Right Cessation
- 2000-12-18 ZA ZA200007593A patent/ZA200007593B/xx unknown
- 2000-12-18 IS IS5775A patent/IS2208B/is unknown
-
2001
- 2001-01-12 HR HR20010039A patent/HRP20010039B1/xx not_active IP Right Cessation
- 2001-01-12 NO NO20010211A patent/NO317601B1/no not_active IP Right Cessation
- 2001-07-10 HK HK01104765A patent/HK1035715A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20013003D0 (no) | Kinolin-derivater | |
ATE228505T1 (de) | Chinolinderivate | |
ATE250036T1 (de) | Chinolinderivate | |
ATE240327T1 (de) | 1,2-annelierte chinolinderivate | |
ATE229005T1 (de) | Chinolinderivate | |
NO20010193D0 (no) | Tiobenzimidazol-derivater | |
ATE236136T1 (de) | Benzosulfonderivate | |
DE69934788D1 (de) | Biozide benzylbiphenylderivative | |
NO20010514L (no) | Aminometylkarboksylsyre-derivater | |
ATE259810T1 (de) | Phenyl-xanthinderivate | |
PT1056716E (pt) | Derivados de ciclo-hexanodiolo | |
DK1115716T3 (da) | 2-phenylpyran-4-on-derivater | |
DK1134219T3 (da) | Cucloalkylsubstituerede aminomethylpyrrolidinderivater | |
ATE233253T1 (de) | Chromanderivate | |
DK1060183T3 (da) | 5-deoxycytidinderivater | |
ATE281436T1 (de) | Chinolin-4-yl-derivate | |
DE59907635D1 (de) | Pyrazolyldioxothiochromanoyl-derivate |